男性性功能障碍 中国就医指南

Male Sexual Dysfunction (MSD) refers to a persistent or recurrent inability to attain and/or maintain an adequate penile erection (erectile dysfunction), ejaculate prematurely (premature ejaculation), experience delayed or absent ejaculation, or sustain sexual desire (hypoactive sexual desire disorder). It encompasses biopsychosocial disturbances affecting sexual response, satisfaction, and interpersonal intimacy. Pathogenesis is multifactorial: organic causes include vascular insufficiency (e.g., endothelial dysfunction from atherosclerosis), neurologic impairment (e.g., diabetic neuropathy, spinal cord injury), endocrine disorders (hypogonadism, hyperprolactinemia, thyroid dysfunction), pharmacologic effects (antidepressants, antihypertensives), and pelvic surgery or trauma. Psychogenic contributors—such as performance anxiety, depression, relationship conflict, and early negative sexual experiences—often coexist with or amplify organic factors. Epidemiologic studies indicate that approximately 30–50% of men aged 40–70 experience some degree of erectile dysfunction, with prevalence rising steadily with age; premature ejaculation affects an estimated 20–30% of adult men globally. Risk factors span modifiable and non-modifiable domains: cardiovascular disease, metabolic syndrome, obesity, smoking, excessive alcohol use, sedentary lifestyle, untreated depression or anxiety, chronic stress, sleep apnea, and aging. Importantly, MSD is strongly associated with underlying systemic pathology—serving as an early sentinel for cardiovascular disease—and warrants comprehensive medical evaluation beyond symptom management. The quality-of-life impact is profound: men report diminished self-esteem, increased psychological distress, reduced work productivity, strained intimate relationships, and higher rates of marital dissatisfaction or separation. Partners often experience decreased sexual satisfaction, emotional distance, and secondary anxiety—highlighting the dyadic nature of sexual health. Untreated MSD correlates with elevated risks of depression, social withdrawal, and reduced overall life satisfaction. Early diagnosis and integrated care—spanning urology, endocrinology, psychology, and reproductive medicine—are essential to address both physiological mechanisms and psychosocial consequences. In the Department of Reproductive Medicine, MSD evaluation emphasizes fertility implications (e.g., ejaculatory failure impairing conception), hormonal profiling (testosterone, prolactin, LH, FSH, SHBG), vascular assessment, and personalized behavioral interventions alongside pharmacotherapy.

# 男性性功能障碍治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

• •适用人群：轻中度勃起功能障碍（ED）、早泄（PE）初诊者，无器质性病变或合并可控慢性病（如2型糖尿病、高血压稳定期）
• •药物治疗（含处方药+随访）：

- SSRIs类（达泊西汀）：480–960元/月（按疗程3个月计）

• •心理行为干预+性教育：2000–4500元/疗程（含6次个体咨询+伴侣共同参与）
• •基础检查费：阴茎血流多普勒超声+激素六项+血糖血脂：860–1120元

二、手术/微创介入方案

• •适用人群：重度血管性ED经药物无效、阴茎动脉狭窄≥70%或静脉漏确诊者；佩罗尼病伴严重弯曲影响插入者
• •阴茎假体植入术（三件套）：8.5–14.2万元（含假体耗材、麻醉、住院5–7天）
• •阴茎背神经选择性阻断术（限早泄明确神经高敏者）：2.8–4.6万元
• •术前全套评估：阴茎海绵体灌注试验+动态超声+夜间阴茎胀大监测（NPT）：2100–3300元

三、特殊复杂情况方案

• •糖尿病相关ED合并神经病变+血管病变：联合干细胞局部注射（临床研究阶段）：3.2–6.8万元/疗程（含GMP级细胞制备及2次介入）
• •根治性前列腺癌术后ED：真空负压装置（VCD）长期管理+低强度脉冲超声（Li-ESWT）：首年总费用约1.5–2.9万元

四、方案快速选择指南

• •预算＜5000元/年：首选PDE5抑制剂+生活方式干预
• •追求根治且预算＞8万元：三件套假体植入（5年无故障率＞92%）
• •年轻早泄患者（＜40岁）：达泊西汀联合行为训练（性价比最优）
• •合并糖尿病/心血管病者：必须先完成血管与神经功能精准评估再定方案